Thompson Michael¹, Schneider Katrin², Clarke Olivia³, Becker Jonas⁴, Wagner Helena⁵, Müller Thomas⁶
ABSTRACT:
Background: Liquid biopsy has emerged as a transformative tool in oncology, enabling non-invasive detection and monitoring of solid tumors through circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes. Methods and Results: This review synthesizes evidence from 150+ studies on the clinical utility of liquid biopsy in tracking tumor evolution, detecting minimal residual disease (MRD), and predicting therapy resistance. Conclusion: While challenges in standardization and sensitivity persist, liquid biopsy is poised to revolutionize real-time cancer monitoring and personalized treatment strategies.